Novartis has reported that patients with polycythemia vera, a type of blood cancer, showed an improvement in their condition compared with the best available therapy following treatment with the JAK inhibitor Jakavi (ruxolitinib). ---Subscribe to MedNous to access this article--- Company News Clinical Research
